|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 10/22/2018 4:39:27 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Agricultural Education Policy
Biomass Programs (Non-Funding)
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
EPA Regulations on Biotechnology
---H.R. 1029 Pesticide Registration Act
---Efficient Science-Based Reviews of Biotech Products
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
Funding for Biomass Crop Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 5961/S.2476: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---H.R. 5961/S.2476: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
------Amendment on GE Salmon Labeling
---The Animal Drug User Fee Reauthorization Act of 2018
One Health
---S. 2615: Advancing Emergency Preparedness Through One Health Act
Potential Regulation of New Genetic Editing/Modification Technologies
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Potential Revisions to Part 340 Regulations
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Matthew |
OMara |
|
|
|
Rina |
Singh |
|
|
|
Dan |
Jenkins |
|
|
|
Jordan |
Layson |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---H.R. 5961/S.2476: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
------Amendment on GE Salmon Labeling
---The Animal Drug User Fee Reauthorization Act of 2018
One Health
---S. 2615: Advancing Emergency Preparedness Through One Health Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Dana |
O'Brien |
|
|
|
Jordan |
Layson |
|
|
|
Dan |
Jenkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Energy Basic Research Funding
---Advanced Research Projects Agency-Energy
---DOE Office of Science
---H.R.5895/S.2975: Energy and Water Development and Related Agencies Appropriations Act for FY 2019
Funding for Antimicrobial Resistance Programs
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for Biofuels
---H.R. 2: Agriculture and Nutrition Act
---S.3042: Agriculture Improvement Act
---H.R.5895/S.2975: Energy and Water Development and Related Agencies Appropriations Act for FY 2019
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for Biomass Crop Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S.3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for Biorefineries
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S.3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for FDA
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for National Institutes of Health
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for Renewable Chemicals/Bio-based Products
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program
---H.R. 2: Agriculture and Nutrition Act
---S.3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
---EPA Safer Choice Program
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Kyle |
Kunkler |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program
---H.R. 2: Agriculture and Nutrition Act
---S.3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
---EPA Safer Choice Program
Renewable Chemicals/Bio-based Products (Non-Funding)
---Investment Tax Credit
---Production Tax Credit
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program
---H.R. 2: Agriculture and Nutrition Act
---S.3042: Agriculture Improvement Act
---H.R. 3149/S.1980: Renewable Chemicals Act of 2017
---H.R. 4118/S.2005: Master Limited Partnership Parity Act
---S.3296: Sustainable Chemistry Research and Development Act of 208
Chemical Weapons Convention
---Coverage of Unscheduled Biomediated Chemicals
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), White House Office, Natl Security Council (NSC), Commerce - Dept of (DOC), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Rina |
Singh |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---March-In Rights
Foreign Drug Data Protection Laws
Intellectual Property International Enforcement
---Compulsory Licensing
---Chile
---Malaysia
Inter Partes Review
---Implementation of the America Invents Act of 2011
---H.R. 5340/S. 1390: STRONGER Patents Act
---H.R. 6264: Restoring America's Leadership Act
---Biomedical Innovation Protection Act of 2018 (Discussion Draft House/Senate)
North American Free Trade Agreement (NAFTA) Renegotiation
---IP Provisions
Patent Reform
---H.R. 5340/S. 1390: STRONGER Patents Act
Compulsory Licensing
---H.R. 6505: Medicare Negotiation and Competitive Licensing Act of 2018
Patent Fees
---S. 3416: USPTO Fees Act
Diversity of Patent Authorship
---H.R. 6390/S.3483: SUCCESS Act
Small Business IP Training
---H.R. 2655/S.791: Small Business Innovation Protection Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Melissa |
Brand |
|
|
|
Matthew |
OMara |
|
|
|
Jordan |
Layson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Importation
---S.469: Affordable and Safe Prescription Drug Importation Act
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
---H.R. 5961/S.2476: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
------Amendment on GE Salmon Labeling
---The Animal Drug User Fee Reauthorization Act of 2018
Opioid Crisis
---NIH Research
---FDA Reforms
---Coverage and Reimbursement
---Transparency
---H.R. 5590: Opioid Addiction Action Plan Act
---H.R. 5002: Advancing Cutting Edge Research Act
---H.R. 5473: Better Pain Management Through Better Data Act
---H.R. 5806: 21st Century Tools for Pain Addiction Treatment
---H.R. 6: SUPPORT for Patients and Communities Act
---S.2665: Providing Clarity in Development of Pain Treatment
---S.2669: Advancing Innovation in Alternative Pain and Addiction Therapies Act
---S.2680: Opioid Crisis Response Act
---S.2769: HEAL Act
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Dana |
OBrien |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Kyle |
Kunkler |
|
|
|
Dan |
Jenkins |
|
|
|
Aiken |
Hackel |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
---Toomey Amendment to H.R.6147 - Interior, Environment, Financial Services and General Government, Agriculture, Rural Development, Food and Drug Administration, and Transportation, Housing and Urban Development Appropriations Act for FY 2019
Biomass Programs (Non-Funding)
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
Biorefineries (non-funding)
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
Energy Basic Research Funding
---DOE Office of Science
---Advanced Research Projects Agency-Energy
---H.R.5895/S.2975: Energy and Water Development and Related Agencies Appropriations Act for FY 2019
Funding for Biofuels
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 5895/S.2975: Energy and Water Development and Related Agencies Appropriations Act for FY 2019
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for Biomass Crop Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for Biorefineries
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Renewable Fuel Standard (RFS)
---Changes to the Point of Obligation under the RFS
---RFS Reform
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
---H.R. 5212/S.2519: Greener Fuels Act
---EPA's Issuance of Small Refinery Waivers
---Administratively Extend Reid Vapor Pressure (RVP) relief to E15
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Labeling
---Efficient Science-Based Review of Biotech Products
---FDA Proposed Guidance on Gene Editing
--------Amendment on GE Salmon Labeling
---The Animal Drug User Fee Reauthorization Act of 2018
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Jordan |
Layson |
|
|
|
Dan |
Jenkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
---Toomey Amendment to H.R.6147 - Interior, Environment, Financial Services and General Government, Agriculture, Rural Development, Food and Drug Administration, and Transportation, Housing and Urban Development Appropriations Act for FY 2019
Biomass Programs (Non-Funding)
---Reauthorization of Biomass Crop Assistance Program
---Reauthorization of Biomass R&D Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
Biorefineries (non-funding)
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
Energy Basic Research Funding
---DOE Office of Science
---Advanced Research Projects Agency-Energy
---H.R.5895/S.2975: Energy and Water Development and Related Agencies Appropriations Act for FY 2019
Funding for Biofuels
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 5895/S.2975: Energy and Water Development and Related Agencies Appropriations Act for FY 2019
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for Biomass Crop Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for Biorefineries
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---H.R. 2: Agriculture and Nutrition Act
---S. 3042: Agriculture Improvement Act
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Renewable Fuel Standard (RFS)
---Changes to the Point of Obligation under the RFS
---RFS Reform
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
---H.R. 5212/S.2519: Greener Fuels Act
---EPA's Issuance of Small Refinery Waivers
---Administratively Extend Reid Vapor Pressure (RVP) relief to E15
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Drug Discount Program
---Program Implementation & Oversight
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
---H.R. 4710: 340B Pause Act
---H.R. 5598: 340B Optimization Act
---S. 2453: Ensuring the Value of the 340B Program Act
Antibiotic & Diagnostic Tax Credit
---H.R. 1840: Reinvigorating Antibiotic and Diagnostic Innovation
Biodefense Research, Development and Procurement Issues (Non-funding)
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---Transfer of Authority for National Strategic Stockpile
------S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
---H.R. 6378/S.2852: Pandemic and All-Hazards Preparedness and Innovation Act (PAHPAIA)
---National Biodefense Strategy
Biosimilars
---Access to Samples for Testing
---Coding
---Naming
---Interchangeability and Pharmacy Substitution
---S. 974/H.R. 2212: CREATES Act of 2017
Drug Evaluation and Review
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Proposed Rule on Changes to Drug Labeling
---Patient-Focused Drug Development
---Prescription Drug User Fee Act (PDUFA) VI Implementation
---FDA Management & Financial Accountability
---FDA Hiring Flexibility
---Priority Review Voucher Program
---Regulatory Reform & Modernization
---Use of Real World Evidence
Drug Importation
---S.469: Affordable and Safe Prescription Drug Importation Act
Drug Manufacturing, Quality & Distribution
---Pharmacy Compounding & Oversight
---Drug Shortages
---Supply Chain Integrity and Traceability
---Counterfeiting
Drug Pricing
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---S. 1348: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017
---S. 1369 / H.R. 2974: Stop Price Gouging Act
---S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act
---S. 771: Improving Access to Affordable Prescription Drugs
---H.R. 6505: Medicare Negotiation and Competitive Licensing Act of 2018
Drug Product Communications
---H.R. 1703: The Medical Products Communications Act of 2017
---S. 2157: Drug-Price Transparency in Communications Act
---Direct to Consumer Advertising Disclosures
------H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
------H.R. 6157: Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Foreign Drug Data Protection Laws
Funding for Antimicrobial Resistance Programs
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 3219: Department of Defense Appropriations Act for FY 2018
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for FDA
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
Funding for National Institutes of Health
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Generic Drug Entry
---Access to Samples for Testing
---Generic Drug Application Review Reforms
---S. 974/H.R. 2212: CREATES Act of 2017
---H.R. 749: Lower Drug Costs Through Competition Act
Medicaid
---Drug Benefit Design
---Pricing and Rebates
---Average Manufacturer Price Calculations
North American Free Trade Agreement (NAFTA) Renegotiation
---Pricing and Reimbursement Provisions
---IP Provisions
Opioid Crisis
---NIH Research
---FDA Reforms
---Coverage and Reimbursement
---Transparency
---H.R. 5590: Opioid Addiction Action Plan Act
---H.R. 5002: Advancing Cutting Edge Research Act
---H.R. 5473: Better Pain Management Through Better Data Act
---H.R. 5806: 21st Century Tools for Pain Addiction Treatment
---H.R. 6: SUPPORT for Patients and Communities Act
---S.2665: Providing Clarity in Development of Pain Treatment
---S.2669: Advancing Innovation in Alternative Pain and Addiction Therapies Act
---S.2680: Opioid Crisis Response Act
---S.2769: HEAL Act
Orphan Drug Issues
---Tax Credit
Reimbursement for Innovative Products
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---S. 1688: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2017
---S. 771: Improving Access to Affordable Prescription Drugs
---H.R. 6505: Medicare Negotiation and Competitive Licensing Act of 2018
Trade and Foreign Drug Price Controls
UN High Level Commission on Access to Medicines
---IP Proposals
Vaccines and Infectious Diseases
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
---Vaccine Safety
---Adult Immunization Education
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Natl Security Council (NSC), White House Office, U.S. Trade Representative (USTR), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Joseph |
Damond |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
John |
Murphy |
|
|
|
Cameron |
Arterton |
|
|
|
Matt |
O'Mara |
|
|
|
Aiken |
Hackel |
|
|
|
Melissa |
Brand |
|
|
|
Hans |
Sauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---Transfer of Authority for National Strategic Stockpile
------S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
---H.R. 6378/S.2852: Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAIA)
---National Biodefense Strategy
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Defense - Dept of (DOD), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
------Transfer of Authority for National Strategic Stockpile
---H.R. 6378/S.2852: Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAIA)
---National Biodefense Strategy
Funding for Antimicrobial Resistance Programs
---H.R. 5961/S.2976: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2019
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for National Institutes of Health
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---S.3158: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Natl Security Council (NSC), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid
---Drug Benefit Design
---Pricing and Rebates
---Average Manufacturer Price Calculation
Reimbursement for Innovative Products
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---S. 1688: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2017
---S. 771: Improving Access to Affordable Prescription Drugs
---H.R. 6505: Medicare Negotiation and Competitive Licensing Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
John |
Murphy |
|
|
|
David |
Lachmann |
|
|
|
Jamie |
Gregorian |
|
|
|
Aiken |
Hackel |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Market Enhancements
---SEC Small Business Forum
---Amended Definition of Smaller Reporting Company
---S. 488: JOBS and Investor Confidence Act
Proxy Advisory Services
---Impact of Policies on Small Public Companies
---H.R. 4015: Corporate Governance Reform and Transparency Act of 2017
---H.R. 10: Financial Choice Act
Sarbanes Oxley Section 404 (b)
---H.R. 1645/S. 2126: Fostering Innovation Act
---Small Issuer Exemption
---H.R. 10: Financial Choice Act
---H.R. 3978: TRID Improvement Act
Short Selling Transparency
Small Business IP Training
---H.R. 2655/S.791: Small Business Innovation Protection Act of 2017
XBRL Exemption for Small Public Companies
---H.R. 5054: Small Company Disclosure Simplification Act
---H.R. 10: Financial Choice Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cartier |
Esham |
|
|
|
Cameron |
Arterton |
|
|
|
Lisa |
Schaefer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Production Tax Credit Extension
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
Capital Formation Investment Incentives
---Reform of Net Operating Loss Rules
---H.R. 6756: American Innovation Act of 2018
Orphan Drug Issues
---Tax Credit
Renewable Chemicals/Bio-based Products (Non-Funding)
---Investment Tax Credit
---Production Tax Credit
---HR 3149/S. 1980: Renewable Chemicals Act of 2017
---H.R. 4118/S. 2005: Master Limited Partnership Parity Act
Qualified Small Business Stock (QSBS)
Research & Development Tax Credit Reforms
---Refundable R&D Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
|
Cartier |
Esham |
|
|
|
Cameron |
Arteron |
|
|
|
Jamie |
Gregorian |
|
|
|
Aiken |
Hackel |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Drug Importation
---S.469: Affordable and Safe Prescription Drug Importation Act
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
Foreign Drug Data Protection Laws
Intellectual Property International Enforcement
---Compulsory Licensing
---Chile
---Malaysia
North American Free Trade Agreement (NAFTA) Renegotiation
---IP Provisions
---Pricing and Reimbursement Provisions
---Ag-Biotech Provisions
Trade and Foreign Drug Price Controls
UN High Level Commission on Access to Medicines
---IP Proposals
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Hans |
Sauer |
|
|
|
Kyle |
Kunkler |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |